TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ascletis Pharma, Inc. ( (HK:1672) ) has issued an update.
Ascletis Pharma Inc. announced promising results from its Phase Ib study of ASC30, an oral GLP-1 receptor agonist, at the European Association for the Study of Diabetes Annual Meeting. The study demonstrated significant weight reduction in participants with obesity and confirmed the drug’s safety and tolerability, with only mild to moderate gastrointestinal side effects. This development highlights Ascletis’ potential to impact the obesity treatment market positively and underscores its commitment to advancing effective therapeutic solutions.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a pharmaceutical company focused on developing innovative therapies, particularly in the field of metabolic diseases such as obesity. The company is known for its strong research and development capabilities, aiming to provide differentiated treatment options in its market sector.
Average Trading Volume: 8,566,753
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.67B
Learn more about 1672 stock on TipRanks’ Stock Analysis page.